Lundbeckfond Invest A/S - Nov 4, 2021 Form 3 Insider Report for IO Biotech, Inc. (IOBT)

Role
10%+ Owner
Signature
Lundbeckfond Invest A/S, by: /s/ Brian Burkavage, Attorney-in-Fact for Christian Elling, Managing Partner, and Lene Skole, Chief Executive Officer
Stock symbol
IOBT
Transactions as of
Nov 4, 2021
Transactions value $
$0
Form type
3
Date filed
11/4/2021, 09:32 PM
Next filing
Nov 12, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IOBT Series B Preferred Stock Nov 4, 2021 Common Stock 2.01M Direct F1
holding IOBT Series C Preferred Stock Nov 4, 2021 Common Stock 1.89M Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series B Preferred Stock beneficially owned by the reporting person will automatically convert, for no additional consideration, into the number of shares of Common Stock reported in Column 3. These shares of Series B Preferred Stock have no expiration date.
F2 Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series C Preferred Stock beneficially owned by the reporting person will automatically convert, for no additional consideration, into the number of shares of Common Stock reported in Column 3. These shares of Series C Preferred Stock have no expiration date.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney